Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Viatris Inc. - Common Stock
(NQ:
VTRS
)
9.180
+0.250 (+2.80%)
Official Closing Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Viatris Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Viatris Eye Drops Data Shows Promise For Blurred Near Vision
June 26, 2025
Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.
Via
Benzinga
3 Unprofitable Stocks with Mounting Challenges
June 17, 2025
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Via
StockStory
3 Healthcare Stocks with Questionable Fundamentals
June 13, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...
Via
StockStory
Topics
Stocks
VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review
June 09, 2025
Medication company Viatris (NASDAQ:VTRS) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. Its non-GAAP EPS of $0.50 per share was 2.3%...
Via
StockStory
Topics
Economy
World Trade
Peering Into Viatris's Recent Short Interest
May 22, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
May 08, 2025
Via
Benzinga
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
June 06, 2025
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.
Via
Benzinga
3 Stocks Under $10 Skating on Thin Ice
May 23, 2025
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be...
Via
StockStory
What's going on in today's session: S&P500 movers
May 15, 2025
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.
Via
Chartmill
What's going on in today's session: S&P500 movers
May 14, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via
Chartmill
Top S&P500 movers in Thursday's session
May 08, 2025
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via
Chartmill
Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars
May 08, 2025
Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS guidance.
Via
Benzinga
Discover which S&P500 stocks are making waves on Thursday.
May 08, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via
Chartmill
Viatris Q1 Earnings Exceed Wall Street Expectations, Company Raises Full-Year Profit Outlook: Retail’s Positive
May 08, 2025
The firm increased its full-year adjusted EPS guidance to $2.16 to $2.30 from its previous guidance of $2.12 to $2.26, including the impact of share repurchases.
Via
Stocktwits
Topics
World Trade
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
May 08, 2025
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Via
Benzinga
Topics
ETFs
Government
These S&P500 stocks that are showing activity before the opening bell on Thursday.
May 08, 2025
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?
Via
Chartmill
Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday
May 08, 2025
Via
Benzinga
Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%
May 08, 2025
Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance...
Via
StockStory
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.
May 07, 2025
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Via
Chartmill
Viatris Earnings: What To Look For From VTRS
May 07, 2025
Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow morning. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
May 06, 2025
Via
Benzinga
Wall Street Mixed Ahead Of Fed Meeting, Alphabet Sinks: What's Driving Markets Wednesday?
May 07, 2025
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET.
Via
Benzinga
Topics
Economy
2 S&P 500 Stocks Worth Investigating and 1 to Avoid
May 05, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...
Via
StockStory
Topics
Stocks
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
April 28, 2025
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Reasons VTRS is Risky and 1 Stock to Buy Instead
April 24, 2025
Viatris’s stock price has taken a beating over the past six months, shedding 33% of its value and falling to $7.69 per share. This was partly due to its softer quarterly results and might have...
Via
StockStory
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
April 21, 2025
Via
Benzinga
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
April 17, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
3 Hated Stocks with Mounting Challenges
April 10, 2025
Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value...
Via
StockStory
Topics
Supply Chain
3 Beaten-Down Stocks That Are Trading Below Their Book Values
April 09, 2025
Via
The Motley Fool
Viatris Agrees To $335 Million Opioid Settlement Framework
April 07, 2025
Viatris reached a $335 million settlement framework to resolve opioid lawsuits, addressing over 1,000 U.S. and Canadian legal claims tied to its products.
Via
Benzinga
Topics
Lawsuit
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.